Key highlights
- VDPHL01 achieved a mean increase of 36.4 hairs/cm² in the twice-daily dose group versus 6.6 hairs/cm² for placebo
- Statistically significant hair growth was observed as early as Month 2, the earliest time point measured
- Patient-reported outcomes showed 68.7% of participants in the BID arm achieved improved or much improved hair coverage
- The clinical trial database now includes over 1,000 participants across two successful registration-directed studies
- Safety data showed no treatment-related serious adverse events or adverse events of cardiac origin
Phase 3 Trial Performance
Veradermics reported that its Study ‘304’ evaluating VDPHL01, a proprietary extended-release oral minoxidil formulation, reached its primary endpoints at Month 6. The trial enrolled 536 male patients with mild-to-moderate pattern hair loss across three arms: once-daily 8.5mg, twice-daily 8.5mg, and placebo. Both active arms showed superior hair growth compared to placebo with a p-value of less than 0.0001. Specifically, non-vellus Target Area Hair Count increases reached 28.6 hairs/cm² for the once-daily group and 36.4 hairs/cm² for the twice-daily group. Statistical separation from placebo was established at the earliest measurement point in Month 2, indicating rapid therapeutic onset.
Clinical and Regulatory Significance
- The data represents the full placebo-controlled set required to support an FDA New Drug Application for VDPHL01
- VDPHL01 is positioned to be the first non-hormonal oral therapeutic for pattern hair loss in nearly 30 years
- Consistency across Study ‘304’ and the previous Study ‘302’ reinforces the efficacy profile of the extended-release formulation
- Absence of cardiac-origin adverse events addresses a primary safety concern associated with traditional oral minoxidil use
- Total registration-directed data now covers over 1,000 participants across the clinical program
Business and Pipeline Overview
Based in New Haven, Connecticut, Veradermics is a late-stage biopharmaceutical firm specializing in dermatological treatments. The company’s flagship pipeline candidate, VDPHL01, utilizes a novel delivery system for minoxidil to improve the clinical profile for androgenetic alopecia. Beyond its lead program in male pattern hair loss, the company is advancing a registration-directed Phase 2/3 Study ‘306’ for female pattern hair loss, with results anticipated in the first half of 2027. Veradermics transitioned to the public markets in February 2026 and currently operates as an emerging growth company without commercial product revenue or an order backlog.
Financial Position and Market Context
Veradermics maintains a robust liquidity position following its initial public offering and a subsequent $414.4 million capital raise in April 2026. As of August 2026, the company reported cash, cash equivalents, and marketable securities totaling $819.9 million. Management expects these reserves to fund operations and capital expenditures into 2030. The company’s market capitalization sits at approximately $4.55 billion, though the stock has seen a 16.87% decline over the past week leading up to this announcement. Future financial performance remains closely tied to the upcoming FDA submission timeline and potential commercial launch in the U.S. market.
Up 17.7% since our story on 19 Oct: $108.82 when we broke it → $128.05 at the close on 16 Nov. Daily closing prices. Source: Yahoo Finance.
Show the prices
| 19 Oct | $122.28 |
|---|---|
| 20 Oct | $127.11 |
| 21 Oct | $136.66 |
| 22 Oct | $138.49 |
| 23 Oct | $138.78 |
| 26 Oct | $137.39 |
| 27 Oct | $140.72 |
| 28 Oct | $143.83 |
| 29 Oct | $143.85 |
| 30 Oct | $139.69 |
| 2 Nov | $129.53 |
| 3 Nov | $133.61 |
| 4 Nov | $136.51 |
| 5 Nov | $128.60 |
| 6 Nov | $138.78 |
| 9 Nov | $143.95 |
| 10 Nov | $148.44 |
| 11 Nov | $156.56 |
| 12 Nov | $135.29 |
| 13 Nov | $129.66 |
| 16 Nov | $128.05 |
| Date | Announcement | Amount |
|---|---|---|
| 11 Aug 2026 | Financial results for second quarter 2026 and clinical pipeline updatesSource: SEC filing | – |
| 15 Jul 2026 | Positive topline results from Phase 2 Study '207' of VDPHL01 in female pattern hair lossSource: SEC filing | – |
| 29 Apr 2026 | Pricing of upsized public offering and concurrent private placementSource: SEC filing | $414.4 Million |
| 27 Apr 2026 | Positive topline results from Phase 2/3 Study '302' of VDPHL01 in male pattern hair lossSource: SEC filing | – |
| 03 Feb 2026 | Pricing of upsized initial public offering (IPO) on the NYSESource: pharmexec.com | $256.3 Million |
| Share price | $108.82 |
|---|---|
| Market cap | $4.5B |
| 1-month price change | +6.25% |
| Sector | HealthcareBiotechnology |
Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.
SEC filing by Veradermics, Incorporated announcing positive topline data from its Phase 3 clinical trial of VDPHL01.
Track Veradermics, Inc live
Get the next Veradermics, Inc SEC filing seconds after it lands.



